The U.S. Food and Drug Administration (FDA) has announced that it will not object to claims that “consuming eicosapentaenoic acid (EPA) and docosahexaenoic (DHA) omega-3 fatty acids in food or dietary supplements may reduce the risk of hypertension and coronary heart disease.” FDA’s research on the claim included reviewing more than 700 studies and 22 public comments submitted on the subject.

The approved qualified health claims include that EPA and DHA “may help lower blood pressure” and “reduce the risk for hypertension” but also reference that “FDA has concluded that the evidence is inconsistent and inconclusive.”

About The Author


For decades, manufacturers, distributors and retailers at every link in the food chain have come to Shook, Hardy & Bacon to partner with a legal team that understands the issues they face in today's evolving food production industry. Shook attorneys work with some of the world's largest food, beverage and agribusiness companies to establish preventative measures, conduct internal audits, develop public relations strategies, and advance tort reform initiatives.